Abstract

ObjectivesTo evaluate effect of rectal ozone in severe COVID-19 pneumonia and to compare it to standard of care (SOC).Material and MethodsIn a case-control study, 14 patients with severe bilateral COVID-19 pneumonia (positive RT-PCR), treated with SOC and rectal ozone, were evaluated before-and-after treatment and compared with SOC (14 patients) in a 10-day follow-up period. Ozone protocol consisted of 8 sessions (1 session/day) of intra-rectal ozone (150 mL volume, 35 μg/mL concentration [5.25mg total dose]). The SOC protocol included O2 supply, antivirals (Remdesivir), corticosteroids (Dexamethasone/Metilprednisolone), monoclonal antibodies (Anakinra/Tocilizumab), antibiotics (Azytromicine), and anticoagulants (Enoxaparine). Primary outcome variables were the following: (a) clinical (O2 saturation and O2 supply); (b) biochemical (lymphocyte count, fibrinogen, D-dimer, urea, ferritin, LDH, IL-6, and CRP); (c) radiological Taylor’s scale. Secondary outcome variables were the following: (a) hospitalization length of stay, (b) mortality rate.ResultsAt baseline, ozone/SOC groups were not different on age, comorbidities, O2 saturation, and O2 supply. Patients in the ozone group improved O2 saturation and decrease O2 supply. SOC maintained O2 saturation and required more O2 supply. Lymphocyte count improved only in the ozone group and with statistical difference (p<0.05). Biomarkers of inflammation (fibrinogen, D-dimer, urea, LDH, CRP, and IL-6) decreased in both groups, but only significantly in favor of the ozone group (p<0.05). Ferritin showed a significant decrease in the ozone group but an increase on the SOC group. Radiological pneumonitis decreased on both groups but the decrease was only significant in the ozone group (p<0.0001). Mortality and length of stay, although not significant, were inferior in the ozone group.ConclusionCompassionate use of rectal ozone improved O2 saturation, reduced O2 supply, decreased inflammation biomarkers, and improved Taylor’s radiological scale significantly when compared to the SOC group. Mortality and length of stay were inferior in the ozone group, but this difference was not significant.

Highlights

  • IntroductionAfter the discovery of a new coronavirus in December 2019 on Wuhan, province of China, by the 3rd of March 2020, the World Health Organization (WHO) has declared an exceptional situation of pandemic due to the new SARS-CoV-2 or COVID-19 virus (https://www.who.int/es/dg/speeches/detail/ who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid-19%2D%2D-11-march-2020)

  • After the discovery of a new coronavirus in December 2019 on Wuhan, province of China, by the 3rd of March 2020, the World Health Organization (WHO) has declared an exceptional situation of pandemic due to the new SARS-CoV-2 or COVID-19 virus.Nowadays, there is no effective treatment for the management of SARS-CoV-2 infection or COVID-19 disease

  • Since there is no definite cure for COVID [1], there are 8 clinical trials (CT) that postulate the potential use of ozonized autohemotherapy on the management of COVID-19 disease (1 CT from Turkey, 2 CT from Italy, 2 CT from Spain, and 3 CT from China) but the results, except the CT from Italy, are still unreported [2]

Read more

Summary

Introduction

After the discovery of a new coronavirus in December 2019 on Wuhan, province of China, by the 3rd of March 2020, the World Health Organization (WHO) has declared an exceptional situation of pandemic due to the new SARS-CoV-2 or COVID-19 virus (https://www.who.int/es/dg/speeches/detail/ who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid-19%2D%2D-11-march-2020). There is no effective treatment for the management of SARS-CoV-2 infection or COVID-19 disease. The Spanish Ministry of Health literally states that at the moment there is no evidence from controlled clinical trials to recommend a specific treatment for the SARS-CoV-2 infection in patients with suspected/confirmed COVID-19. Since there is no definite cure for COVID [1], there are 8 clinical trials (CT) that postulate the potential use of ozonized autohemotherapy on the management of COVID-19 disease (1 CT from Turkey, 2 CT from Italy, 2 CT from Spain, and 3 CT from China) but the results, except the CT from Italy, are still unreported [2]. As far as we know, there is only one CT from Cuba which considers rectal ozone as an alternative for the management of COVID-19 infection, but the study is still in phase of recruiting (https://rpcec.sld.cu/ ensayos/RPCEC00000320-Sp)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call